Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer

Onkologie

Volumn 35, Issue 7-8, 2012, Pages 427-431

  Idelevich, Efraim ^a   Kashtan, Hanoch ^a,b   Klein, Yoram ^a,b   Buevich, Victor ^a,b   Baruch, Noa Ben ^a   Dinerman, Michael ^a   Tokar, Margarita ^e   Kundel, Yulia ^c,d   Brenner, Baruch ^c,d  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

5 Fluorouracil; Bevacizumab; Cisplatin; Esophageal cancer; Neoadjuvant therapy

Indexed keywords

BEVACIZUMAB; CISPLATIN; FLUOROURACIL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; LOCALLY ADVANCED RESECTABLE ESOPHAGEAL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 84864583237     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000340072     Document Type: Article

References (18)

1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062-5067.
2. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Radiation Therapy Oncology Group, USA Intergroup: Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-3725.
3. Sjoquist KM, Burmeister BH, Smithers BM, Z alcberg JR, Simes RJ, Barbour A, Gebski V, for the Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011;12:681-692.
4. Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre J-M, Saint-Aubert B, Genève J, Lasser P, Rougier P: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD ulticenter phase III trial. J Clin Oncol 2011;29:1715-1721
5. Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002;359: 1727-1733.
6. Okines A, Cunnigham D: Progress in the multidisciplinary treatment of gastrointestinal cancers, impact on clinical practice: Peri-operative management of gastro-esophageal cancer. Ann Oncol 2008;19(suppl 7):259-265.
7. Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP: Oesopagogastric junction adenocarcinoma: with therapeutic approach? Lancet Oncol 2011;12:296-305.
8. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer H-J, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
9. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011;29:626-631.
10. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.
11. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21:1999-2004.
12. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal cancer. J Clin Oncol 2011;29:868-874.
13. Idelevich E, Buyevich V, Machlenkin S, Ziv- Sokolovsky N, Dinerman M, Brenner B, Kashtan H: Overall survival with cisplatin and 5-fluorouracil neoadjuvant treatment in patients with esophageal cancer: Single-center experience. Onkologie 2008;31:673-677.
14. Machlenkin S, Melzer E, Idelevich E, Ziv- Sokolovsky N, Klein Y, Kashtan H: Endoscopic ultrasound: Doubtful accuracy for restaging esophageal cancer after preopertaive chemotherapy. Isr Med ssoc J 2009;11:166-169.
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979. whqlibdoc.who. int/offset/WHO-OFFSET-48.pdf.
16. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). DCTD, NCI, NIH, DHHS, March 31, 2003. ctep.cancer.gov/ protocolDevelopment/electronic- applications/docs/ctcaev3.pdf.
17. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: Final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91:2165-2174.
18. Pines G, Klein Y, Buyevitz V, Idelevich E, Kashtan H: Disease-related mortality within the first year after subtotal esophagectomy for cancer. Ann Surg Oncol 2011;18:1139-1144.